Evaluating Length of Treatment With PD-1/PD-L1 Inhibitor in Advanced Solid Tumors
University of Pittsburgh
University of Pittsburgh
Hoffmann-La Roche
Hoffmann-La Roche
Medical College of Wisconsin
Genentech, Inc.
Grupo Espanol de Tumores Neuroendocrinos
Immatics US, Inc.
Centre Hospitalier Universitaire de Besancon
invoX Pharma Limited
University Hospital, Essen
University Hospital, Ghent
Fate Therapeutics
Oncovir, Inc.